Corp /De/ Celgene Net Worth

The estimated Net Worth of Corp /De/ Celgene is at least $52.6 Millón dollars as of 18 January 2019. Corp Celgene owns over 706,206 units of Sutro Biopharma Inc stock worth over $31,461,798 and over the last 11 years Corp sold STRO stock worth over $21,114,225.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Corp Celgene STRO stock SEC Form 4 insiders trading

Corp has made over 10 trades of the Sutro Biopharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Corp bought 706,206 units of STRO stock worth $30,366,858 on 18 January 2019.

The largest trade Corp's ever made was buying 4,000,000 units of Sutro Biopharma Inc stock on 27 February 2017 worth over $2,000,000. On average, Corp trades about 919,268 units every 162 days since 2013. As of 18 January 2019 Corp still owns at least 6,824,685 units of Sutro Biopharma Inc stock.

You can see the complete history of Corp Celgene stock trades at the bottom of the page.

What's Corp Celgene's mailing address?

Corp's mailing address filed with the SEC is 86 MORRIS AVENUE, , SUMMIT, NJ, 07901.

Insiders trading at Sutro Biopharma Inc

Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund y Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.

What does Sutro Biopharma Inc do?

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll

Complete history of Corp Celgene stock trades at Acceleron Pharma Inc, CRISPR Therapeutics AG y Sutro Biopharma Inc

Sutro Biopharma Inc executives and stock owners

Sutro Biopharma Inc executives and other stock owners filed with the SEC include:

• William Newell,
  Chief Executive Officer, Director
• William J. Newell J.D.,
  CEO & Director
• Trevor Hallam,
  Chief Scientific Officer
• Arturo Molina,
  Chief Medical Officer
• William J. Newell,
  CEO & Director
• Jane Chung R.Ph.,
  Chief Commercial Officer
• Dr. Trevor J. Hallam,
  Pres of Research & Chief Scientific Officer
• Linda A. Fitzpatrick,
  Chief People & Communications Officer
• Connie Matsui,
  Chairman of the Board
• Shalini Sharp,
  Independent Director
• Joseph Lobacki,
  Independent Director
• Michael Dybbs,
  Independent Director
• John Freund,
  Independent Director
• Daniel Petree,
  Director
• Annie Chang,
  Head of Investor Relations
• Diana Landa,
  Vice President of Regulatory Affairs
• James Panek,
  Director
• Shabbir Anik,
  Chief Technical Operations Officer
• Brunilda Shtylla,
  Vice President - Business Development
• Craig Berman,
  Vice President - Clinical Development
• Kristin Bedard,
  Vice President - Immunobiology
• Carlos Lugo,
  Vice President - Quality and CMC Regulatory Operations
• Regina Cheng,
  Vice President - Finance, Controller
• Linda Fitzpatrick,
  Chief People and Communications Officer
• Edward Albini,
  Chief Financial Officer
• Dr. James R. Swartz Ph.D., Sc.D.,
  Founder
• Dr. Arturo M. Molina FACP, M.D., MS,
  Chief Medical Officer
• Annie J. Chang M.B.A.,
  VP of Investor Relations
• Dr. Arturo M. Molina,
  Chief Medical Officer
• Dr. Nicki Vasquez Ph.D.,
  Chief Portfolio Strategy & Alliance Officer
• David Pauling J.D., M.A.,
  Gen. Counsel
• Dr. Shabbir T. Anik,
  Chief Technical Operations Officer
• Edward C. Albini,
  CFO & Sec.
• Dr. James R. Swartz,
  Founder and Member of Scientific Advisory Board
• Nicki Vasquez,
  CHIEF PORT. STRAT & ALNCE OFCR
• Corp /De/ Celgene,
  
• Michael Jay Ross,
  Director
• Partners Viii, L.P.Alta Par...,
  
• V Bryan Lawlis,
  Director
• Daniel Janney,
  Director
• Stephen Worsley,
  Chief Business Officer
• & Co., Inc.Merck Sharp & Do...,
  
• Venture Partners V Lp Skyli...,
  
• V, Llcilsf Iii, Llcinternat...,
  
• Jane Chung,
  PRESIDENT AND COO
• Venkatesh Srinivasan,
  CHIEF TECH OP OFFICER
• Anne Elizabeth Borgman,
  CHIEF MEDICAL OFFICER
• Sukhi Jagpal,
  
• Hans Peter Gerber,
  CHIEF SCIENTIFIC OFFICER
• Heidi Hunter,
  
• Jon Marc Wigginton,
  
• Barbara Leyman,
  Chief Business Dev. Officer